MA38472B1 - Composé peptidique - Google Patents
Composé peptidiqueInfo
- Publication number
- MA38472B1 MA38472B1 MA38472A MA38472A MA38472B1 MA 38472 B1 MA38472 B1 MA 38472B1 MA 38472 A MA38472 A MA 38472A MA 38472 A MA38472 A MA 38472A MA 38472 B1 MA38472 B1 MA 38472B1
- Authority
- MA
- Morocco
- Prior art keywords
- peptide compound
- relates
- medicament
- receptors
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Abstract
La présente invention concerne un nouveau composé peptidique ayant pour effet d'activer les récepteurs au glp-1 et les récepteurs au gip, ainsi que l'utilisation dudit composé peptidique en tant que médicament. L'invention concerne, plus précisément, un peptide contenant une séquence partielle représentée par la formule (i), ou un sel de celui-ci et un médicament en contenant. P
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013111893 | 2013-05-28 | ||
| PCT/JP2014/002772 WO2014192284A1 (fr) | 2013-05-28 | 2014-05-27 | Composé peptidique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38472A1 MA38472A1 (fr) | 2018-01-31 |
| MA38472B1 true MA38472B1 (fr) | 2018-09-28 |
Family
ID=50942304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38472A MA38472B1 (fr) | 2013-05-28 | 2014-05-27 | Composé peptidique |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US9200051B2 (fr) |
| EP (1) | EP3004155B1 (fr) |
| JP (2) | JP6429799B2 (fr) |
| KR (1) | KR102229051B1 (fr) |
| CN (1) | CN105209485B (fr) |
| AP (1) | AP2015008781A0 (fr) |
| AR (1) | AR096440A1 (fr) |
| AU (1) | AU2014272500B2 (fr) |
| CA (1) | CA2908581C (fr) |
| CL (1) | CL2015003031A1 (fr) |
| CY (1) | CY1124790T1 (fr) |
| DK (1) | DK3004155T3 (fr) |
| DO (1) | DOP2015000261A (fr) |
| EA (2) | EA035813B1 (fr) |
| EC (1) | ECSP15044389A (fr) |
| ES (1) | ES2900744T3 (fr) |
| GE (1) | GEP201706762B (fr) |
| HR (1) | HRP20212014T1 (fr) |
| HU (1) | HUE057361T2 (fr) |
| IL (1) | IL242005B (fr) |
| LT (1) | LT3004155T (fr) |
| MA (1) | MA38472B1 (fr) |
| MX (2) | MX373436B (fr) |
| MY (1) | MY172744A (fr) |
| PE (1) | PE20151770A1 (fr) |
| PH (1) | PH12015502391B1 (fr) |
| PL (1) | PL3004155T3 (fr) |
| PT (1) | PT3004155T (fr) |
| SG (1) | SG11201507934PA (fr) |
| SI (1) | SI3004155T1 (fr) |
| TN (1) | TN2015000451A1 (fr) |
| TW (1) | TWI638831B (fr) |
| UA (1) | UA118558C2 (fr) |
| UY (1) | UY35589A (fr) |
| WO (1) | WO2014192284A1 (fr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20212014T1 (hr) | 2013-05-28 | 2022-04-01 | Takeda Pharmaceutical Company Limited | Spoj peptida |
| AR103242A1 (es) | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| CN104846061A (zh) * | 2015-05-07 | 2015-08-19 | 中国药科大学 | 一种glp-1受体激动剂的受体亲和力测定方法 |
| CN105388239B (zh) * | 2015-12-18 | 2018-01-05 | 兆科药业（合肥）有限公司 | 一种多肽固相合成的监测方法 |
| JP6995042B2 (ja) * | 2016-05-24 | 2022-02-04 | 武田薬品工業株式会社 | ペプチド化合物 |
| EP3551202B1 (fr) | 2016-12-06 | 2024-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés d'amélioration de l'efficacité de médicaments à base d'incrétine chez les sujets en ayant besoin |
| JOP20180028A1 (ar) * | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| WO2019140030A1 (fr) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Polythérapie |
| MX2020007410A (es) | 2018-01-23 | 2020-11-09 | Gila Therapeutics Inc | Formulaciones, composiciones y métodos farmacéuticos de péptido yy. |
| MA52483A (fr) * | 2018-05-04 | 2021-03-10 | Novo Nordisk As | Dérivés de gip et leurs utilisations |
| JP2021530544A (ja) * | 2018-07-23 | 2021-11-11 | イーライ リリー アンド カンパニー | 糖尿病のためのｇｉｐ／ｇｌｐ１共アゴニストを使用する方法 |
| CN110818771B (zh) * | 2018-08-14 | 2023-01-17 | 陈铭 | 使用氨基酸离子液体的羰基硫介导多肽合成 |
| JP7511548B2 (ja) * | 2018-09-24 | 2024-07-05 | 武田薬品工業株式会社 | Ｇｉｐ受容体アゴニストペプチド化合物及びその使用 |
| WO2020067557A2 (fr) * | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Composés peptidiques agonistes du récepteur du gip et leurs utilisations |
| BR112022001081A2 (pt) * | 2019-08-19 | 2022-05-24 | Lilly Co Eli | Métodos para produzir análogos de incretina |
| WO2021066600A1 (fr) | 2019-10-04 | 2021-04-08 | 한미약품 주식회사 | Glucagon, composition comprenant un agoniste double du récepteur de glp-1 et du récepteur de gip et utilisation thérapeutique associée |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| AU2021241257A1 (en) * | 2020-03-25 | 2022-10-13 | Takeda Pharmaceutical Company Limited | QD dosing of GIP receptor agonist peptide compounds and uses thereof |
| EP4171662A1 (fr) * | 2020-03-31 | 2023-05-03 | Antaros Medical AB | Agonistes sélectifs du récepteur de gip comprenant une fraction chélatante à des fins d'imagerie et de thérapie |
| JP7581385B2 (ja) | 2020-07-22 | 2024-11-12 | ノヴォ ノルディスク アー／エス | 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
| IL299707A (en) | 2020-07-22 | 2023-03-01 | Novo Nordisk As | Co-agonists for GLP-1 and GIP receptors |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| CA3222051A1 (fr) | 2021-06-01 | 2022-12-08 | Nanjing Zhihe Medicine Technology Co., Ltd. | Derive polypeptidique ayant un effet d'activation a double cible de glp-1r et de gipr, procede de preparation associe et son utilisation |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN119522233A (zh) * | 2022-07-13 | 2025-02-25 | 杭州中美华东制药有限公司 | Glp-1/gip双激动剂及其制备方法和用途 |
| JP2025523981A (ja) * | 2022-07-20 | 2025-07-25 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための医薬製剤及び方法 |
| WO2024059674A1 (fr) | 2022-09-15 | 2024-03-21 | Eli Lilly And Company | Composés agonistes doubles de gip et de glp-1 |
| CN121001710A (zh) | 2022-12-30 | 2025-11-21 | 阿尔吉法玛公司 | 提高口服多肽治疗剂的全身生物利用度的组合物和方法 |
| WO2024165571A2 (fr) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibiteurs d'expression et/ou de fonction |
| EP4714434A1 (fr) | 2023-05-19 | 2026-03-25 | Aulbio Co., Ltd. | Microsphère comprenant du tirzépatide, son procédé de préparation, et composition pharmaceutique la comprenant |
| KR20260022948A (ko) | 2023-06-09 | 2026-02-20 | 썬 파마슈티컬 인더스트리스 리미티드 | Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제 |
| KR20260032481A (ko) | 2023-06-30 | 2026-03-09 | 질랜드 파마 에이/에스 | 병용 요법 |
| TW202529796A (zh) * | 2023-11-22 | 2025-08-01 | 大陸商杭州中美華東製藥有限公司 | Glp-1r/gipr雙標靶激動劑在製備動物藥的用途 |
| KR102937241B1 (ko) | 2023-11-30 | 2026-03-11 | 노보 노르디스크 에이/에스 | Glp-1, gip, 및 아밀린 수용체의 삼중작용제 |
| WO2025125576A2 (fr) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibiteurs d'expression et/ou de fonction |
| EP4686757A1 (fr) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibiteurs d expression et/ou de fonction |
| WO2025133348A1 (fr) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibiteurs d'expression et/ou de fonction |
| TW202542174A (zh) * | 2023-12-29 | 2025-11-01 | 大陸商杭州中美華東製藥有限公司 | Glp-1/gip雙激動劑的固相合成方法 |
| TW202535912A (zh) * | 2024-01-12 | 2025-09-16 | 大陸商杭州中美華東製藥有限公司 | 長效glp-1/gip雙激動劑的鼻腔遞送藥物組合物 |
| WO2025149039A1 (fr) * | 2024-01-12 | 2025-07-17 | 杭州中美华东制药有限公司 | Composition pharmaceutique d'agoniste double de glp-1/gip à action prolongée |
| WO2025196502A1 (fr) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Inhibiteurs de choline kinase utilisés en tant que traitement thérapeutique contre l'obésité |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| DE69737916T2 (de) | 1996-11-12 | 2008-04-03 | Novo Nordisk A/S | Verwendung von GLP-1 Peptiden |
| WO1999047161A1 (fr) | 1998-03-19 | 1999-09-23 | Bionebraska, Inc. | Regulation de l'appetit chez les humains par un compose se liant a un recepteur de peptide de type glucagon |
| EP1100530B1 (fr) | 1998-07-31 | 2003-10-08 | Novo Nordisk A/S | In vitro stimulation de la proliferation des cellules de langerhans beta pancreatique |
| KR100458748B1 (ko) | 1998-12-07 | 2004-12-03 | 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 | Ｇｌｐ-1 유사체 |
| AU5675701A (en) | 2000-05-16 | 2001-11-26 | Sanwa Kagaku Kenkyusho Co | Agents for preventing or ameliorating insulin resistance and/or obesity |
| JP5685355B2 (ja) | 2002-07-04 | 2015-03-18 | ジーランド ファーマ アクティーゼルスカブ | Ｇｌｐ−１および糖尿病の処置方法 |
| EP2210900A3 (fr) | 2003-12-16 | 2010-08-11 | Ipsen Pharma | Analogues du GLP-1 |
| WO2006049681A2 (fr) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Agonistes recepteur y2 neuropeptidiques selectifs |
| SG159551A1 (en) | 2005-02-11 | 2010-03-30 | Amylin Pharmaceuticals Inc | Gip analog and hybrid polypeptides with selectable properties |
| WO2006136374A2 (fr) | 2005-06-20 | 2006-12-28 | Develogen Aktiengesellschaft | Utilisation du gip et/ou de la vitamine d3 et d'analogues correspondants pour ameliorer la differenciation de cellules souches ou progenitrices en cellules productrices d'insuline |
| EP2051725A4 (fr) | 2006-07-11 | 2011-06-15 | Harkness Pharmaceuticals Inc | Procédés de traitement de l'obésité en utilisant des facteurs de satiété |
| AU2007284365A1 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| JO2945B1 (en) | 2006-09-13 | 2016-03-15 | سميث كلاين بيتشام كوربوريشن | Methods of giving prolonged hypoglycemic agents |
| EP1972349A1 (fr) | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | Peptides à fusion GLP-1 associée à un/plusieurs polymères, leur production et utilisation |
| US8710002B2 (en) | 2007-11-23 | 2014-04-29 | Michael Rothkopf | Methods of enhancing diabetes resolution |
| PL2300035T3 (pl) * | 2008-06-17 | 2016-04-29 | Univ Indiana Res & Tech Corp | Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości |
| US8999940B2 (en) | 2008-08-07 | 2015-04-07 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
| WO2010068735A1 (fr) | 2008-12-10 | 2010-06-17 | Glaxosmithkline Llc. | Compositions pharmaceutiques |
| MX2011013625A (es) | 2009-06-16 | 2012-01-20 | Univ Indiana Res & Tech Corp | Compuestos glucagon activo de receptor de gip. |
| EP2450374B9 (fr) | 2009-07-02 | 2016-11-23 | Takeda Pharmaceutical Company Limited | Peptide et son utilisation |
| MX2012008603A (es) * | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| RU2013133803A (ru) | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| EP2694095B1 (fr) | 2011-04-05 | 2018-03-07 | Longevity Biotech, Inc. | Compositions comprenant des analogues du glucagon et leurs procédés de fabrication et d'utilisation |
| CN103764673A (zh) * | 2011-06-10 | 2014-04-30 | 北京韩美药品有限公司 | 葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用 |
| US8575090B2 (en) | 2011-06-10 | 2013-11-05 | Novo Nordisk A/S | Amylin analogues and pharmaceutical compositions thereof |
| WO2013003449A2 (fr) | 2011-06-27 | 2013-01-03 | Phasebio Pharmaceuticals, Inc. | Méthodes de traitement par des agonistes de récepteur du glp-1 |
| JP6126097B2 (ja) | 2011-09-06 | 2017-05-10 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体 |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| JP6228187B2 (ja) | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| US10000542B2 (en) | 2012-05-08 | 2018-06-19 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| US20150182461A1 (en) | 2012-06-19 | 2015-07-02 | Massachussets Institute Of Technology | Mass Production and Size Control of Nanoparticles Through Controlled Microvortices |
| EA029025B1 (ru) | 2012-06-21 | 2018-01-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, проявляющие активность на рецепторе gip |
| WO2013192129A1 (fr) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Analogues du glucagon présentant une activité sur le récepteur du gip |
| CN104968674A (zh) | 2012-12-19 | 2015-10-07 | 诺和诺德股份有限公司 | 具有胆固醇流出活性的新颖的glp-1受体激动剂 |
| LT2934568T (lt) | 2012-12-21 | 2018-02-12 | Sanofi | Dvigubi glp1/gip arba trigubi glp/gip/gliukagono agonistai |
| CA2902352A1 (fr) | 2013-03-14 | 2014-09-18 | Medimmune Limited | Co-agonistes pegyles du glucagon et de glp-1 pour le traitement de l'obesite |
| HRP20212014T1 (hr) | 2013-05-28 | 2022-04-01 | Takeda Pharmaceutical Company Limited | Spoj peptida |
| US10131702B2 (en) | 2013-11-06 | 2018-11-20 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
-
2014
- 2014-05-27 HR HRP20212014TT patent/HRP20212014T1/hr unknown
- 2014-05-27 DK DK14729976.2T patent/DK3004155T3/da active
- 2014-05-27 EA EA201591891A patent/EA035813B1/ru unknown
- 2014-05-27 MA MA38472A patent/MA38472B1/fr unknown
- 2014-05-27 TN TN2015000451A patent/TN2015000451A1/en unknown
- 2014-05-27 KR KR1020157032121A patent/KR102229051B1/ko active Active
- 2014-05-27 AP AP2015008781A patent/AP2015008781A0/xx unknown
- 2014-05-27 ES ES14729976T patent/ES2900744T3/es active Active
- 2014-05-27 PL PL14729976T patent/PL3004155T3/pl unknown
- 2014-05-27 US US14/287,514 patent/US9200051B2/en active Active
- 2014-05-27 CA CA2908581A patent/CA2908581C/fr active Active
- 2014-05-27 EP EP14729976.2A patent/EP3004155B1/fr active Active
- 2014-05-27 AU AU2014272500A patent/AU2014272500B2/en active Active
- 2014-05-27 PE PE2015002124A patent/PE20151770A1/es unknown
- 2014-05-27 GE GEAP201413984A patent/GEP201706762B/en unknown
- 2014-05-27 MX MX2015015464A patent/MX373436B/es active IP Right Grant
- 2014-05-27 AR ARP140102090A patent/AR096440A1/es active IP Right Grant
- 2014-05-27 LT LTEPPCT/JP2014/002772T patent/LT3004155T/lt unknown
- 2014-05-27 MY MYPI2015703438A patent/MY172744A/en unknown
- 2014-05-27 MX MX2019010531A patent/MX388826B/es unknown
- 2014-05-27 UA UAA201510946A patent/UA118558C2/uk unknown
- 2014-05-27 HU HUE14729976A patent/HUE057361T2/hu unknown
- 2014-05-27 UY UY0001035589A patent/UY35589A/es not_active Application Discontinuation
- 2014-05-27 WO PCT/JP2014/002772 patent/WO2014192284A1/fr not_active Ceased
- 2014-05-27 CN CN201480026613.0A patent/CN105209485B/zh active Active
- 2014-05-27 TW TW103118374A patent/TWI638831B/zh active
- 2014-05-27 JP JP2015555470A patent/JP6429799B2/ja active Active
- 2014-05-27 US US14/780,579 patent/US10087229B2/en active Active
- 2014-05-27 SG SG11201507934PA patent/SG11201507934PA/en unknown
- 2014-05-27 PT PT147299762T patent/PT3004155T/pt unknown
- 2014-05-27 EA EA202090593A patent/EA202090593A3/ru unknown
- 2014-05-27 SI SI201431933T patent/SI3004155T1/sl unknown
-
2015
- 2015-10-11 IL IL242005A patent/IL242005B/en active IP Right Grant
- 2015-10-13 CL CL2015003031A patent/CL2015003031A1/es unknown
- 2015-10-14 PH PH12015502391A patent/PH12015502391B1/en unknown
- 2015-10-15 DO DO2015000261A patent/DOP2015000261A/es unknown
- 2015-10-21 EC ECIEPI201544389A patent/ECSP15044389A/es unknown
-
2018
- 2018-06-12 JP JP2018111494A patent/JP6570705B2/ja active Active
-
2021
- 2021-12-15 CY CY20211101100T patent/CY1124790T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38472B1 (fr) | Composé peptidique | |
| MA38390B1 (fr) | Composés tétrahydropyrrolothiazines | |
| MA39246A1 (fr) | Composé hétérocyclique fusionné | |
| BR112017006253A2 (pt) | novos compostos | |
| AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
| EA201501142A1 (ru) | Гетероциклические соединения в качестве средств для борьбы с вредителями | |
| EA201590854A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2 | |
| MA38583B1 (fr) | Dérivés de dolastatine 10 et d'auristatines | |
| EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
| MA37501B1 (fr) | Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1 | |
| AR095523A1 (es) | Derivados piridin-4-ilo | |
| EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| EA201591649A1 (ru) | Составы с органическими соединениями | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| AR100913A1 (es) | Síntesis de complejo de zinc-lisina a partir de cloruro de zinc | |
| EA201692270A1 (ru) | Производные нафтиридиндиона | |
| SV2019005838A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| AR099767A1 (es) | Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2 | |
| MX2015005314A (es) | Compuestos de malononitrilo para controlar plagas animales. | |
| MA39108A1 (fr) | Nouveau composé pour le traitement de l'hypoglycémie sévère | |
| CL2018002422A1 (es) | Preparación que contiene agua de mar a la que se ha agregado un compuesto de potasio. | |
| MA39756B1 (fr) | Nouveau sel de l'ivabradine et son procédé de préparation | |
| AR112111A1 (es) | Tetrahidropiridopirazinas moduladoras de receptores gpr6 | |
| AR095761A1 (es) | Compuestos de dihidropirido pirimidina |